DBV Technologies (NASDAQ:DBVT) Shares Gap Down – What’s Next?

DBV Technologies S.A. (NASDAQ:DBVT)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $18.29, but opened at $17.50. DBV Technologies shares last traded at $18.1570, with a volume of 43,116 shares changing hands.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on DBVT shares. Zacks Research upgraded shares of DBV Technologies from a “strong sell” rating to a “hold” rating in a research report on Monday, September 29th. HC Wainwright reissued a “buy” rating and set a $35.00 price target (up previously from $20.00) on shares of DBV Technologies in a research note on Monday. Guggenheim initiated coverage on DBV Technologies in a research report on Wednesday, December 3rd. They issued a “buy” rating and a $35.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of DBV Technologies in a research report on Monday, December 8th. Finally, Wall Street Zen upgraded DBV Technologies from a “sell” rating to a “hold” rating in a report on Friday, November 28th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $28.05.

DBV Technologies Stock Down 1.0%

The stock has a market cap of $727.30 million, a PE ratio of -3.50 and a beta of -1.10. The company’s fifty day moving average is $14.90 and its 200 day moving average is $11.51.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in DBVT. Vivo Capital LLC acquired a new stake in shares of DBV Technologies in the second quarter valued at about $9,659,000. Nan Fung Trinity HK Ltd. purchased a new position in DBV Technologies in the 2nd quarter worth approximately $340,000. Millennium Management LLC grew its position in DBV Technologies by 26.1% in the third quarter. Millennium Management LLC now owns 337,863 shares of the company’s stock valued at $3,379,000 after acquiring an additional 69,849 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of DBV Technologies during the third quarter valued at approximately $220,000. Finally, Octagon Capital Advisors LP acquired a new position in shares of DBV Technologies during the second quarter worth $9,315,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.